Bain Capital Investors’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-65,679,781
| Closed | -$2.69B | – | 6 |
|
|
2024
Q2 | $2.69B | Hold |
65,679,781
| – | – | 57.02% | 1 |
|
|
2024
Q1 | $2.78B | Hold |
65,679,781
| – | – | 61.94% | 1 |
|
|
2023
Q4 | $2.78B | Buy |
65,679,781
+5,480,052
| +9% | +$232M | 60.39% | 1 |
|
|
2023
Q3 | $1.31B | Hold |
60,199,729
| – | – | 42.08% | 2 |
|
|
2023
Q2 | $1.91B | Sell |
60,199,729
-432,627
| -0.7% | -$13.8M | 28.7% | 3 |
|
|
2023
Q1 | $1.48B | Hold |
60,632,356
| – | – | 26.92% | 3 |
|
|
2022
Q4 | $1.91B | Hold |
60,632,356
| – | – | 41.46% | 1 |
|
|
2022
Q3 | $1.71B | Hold |
60,632,356
| – | – | 41.39% | 1 |
|
|
2022
Q2 | $1.6B | Hold |
60,632,356
| – | – | 33.55% | 1 |
|
|
2022
Q1 | $2.12B | Hold |
60,632,356
| – | – | 30.71% | 2 |
|
|
2021
Q4 | $1.97B | Hold |
60,632,356
| – | – | 23.51% | 3 |
|
|
2021
Q3 | $1.79B | Hold |
60,632,356
| – | – | 21.09% | 3 |
|
|
2021
Q2 | $1.55B | Hold |
60,632,356
| – | – | 15.17% | 3 |
|
|
2021
Q1 | $832M | Hold |
60,632,356
| – | – | 12.25% | 4 |
|
|
2020
Q4 | $1.01B | Buy |
+60,632,356
| New | +$1.01B | 38.09% | 1 |
|